<SEC-DOCUMENT>0001520412-15-001790.txt : 20150817
<SEC-HEADER>0001520412-15-001790.hdr.sgml : 20150817
<ACCEPTANCE-DATETIME>20150817060303
ACCESSION NUMBER:		0001520412-15-001790
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20150817
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20150817
DATE AS OF CHANGE:		20150817

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LEXARIA CORP.
		CENTRAL INDEX KEY:			0001348362
		STANDARD INDUSTRIAL CLASSIFICATION:	METAL MINING [1000]
		IRS NUMBER:				202000871
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0831

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-52138
		FILM NUMBER:		151057655

	BUSINESS ADDRESS:	
		STREET 1:		SUITE 950, 1130 WEST PENDER STREET
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V6E 4A4
		BUSINESS PHONE:		604-602-1675

	MAIL ADDRESS:	
		STREET 1:		SUITE 950, 1130 WEST PENDER STREET
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V6E 4A4

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Lexaria Corp.
		DATE OF NAME CHANGE:	20051229
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
   <TITLE>Lexaria Corp.: Form 8-K - Filed by newsfilecorp.com</TITLE>
   <META name="HandheldFriendly" content="true">
</HEAD>

<BODY style="font-size:10pt;">

<HR noshade align="center" width=100% size=3 color="black">
<A name=page_1></A>
<P align=center><B><FONT size=5>UNITED STATES </FONT></B><BR><B><FONT
size=5>SECURITIES AND EXCHANGE COMMISSION </FONT></B><BR><B>Washington, D.C.
20549 </B></P>
<P align=center><B><FONT size=5>FORM 8-K </FONT></B></P>
<P align=center>Current Report <BR>Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934 </P>
<DIV>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
borderColor=#000000 cellSpacing=0 cellPadding=3 width="100%" border=1>

  <TR vAlign=top>
    <TD align=left colSpan=4>Date of Report (date of earliest event reported):
      August 17, 2015 </TD></TR>
  <TR vAlign=bottom>
    <TD align=center colSpan=4 rowSpan=2><B><FONT size=5><U>LEXARIA CORP.
      </U></FONT></B><BR>(Exact name of registrant as specified in its charter)
    </TD></TR>
  <TR vAlign=bottom></TR>
  <TR vAlign=top>
    <TD align=center rowSpan=3><B><U>Nevada </U></B><BR>(State or other
      jurisdiction of <BR>incorporation) </TD>
    <TD align=center width="33%" rowSpan=3><B><U>000-52138
      </U></B><BR>(Commission File Number) <BR></TD>
    <TD align=center width="33%" colSpan=2 rowSpan=3><B><U>20-2000871
      </U></B><BR>(IRS Employer Identification No.) <BR></TD></TR>
  <TR vAlign=top></TR>
  <TR vAlign=top></TR>
  <TR vAlign=top>
    <TD align=left colSpan=3>#950 &#150; 1130 West Pender Street, Vancouver,
      British Columbia, Canada V6E 4A4 </TD>
    <TD align=left width="28%">&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left colSpan=4>Registrant's telephone number, including area
      code: (604) 602-1675 </TD></TR>
  <TR vAlign=bottom>
    <TD align=center colSpan=4>(Former name or former address, if changed
      since last report.) </TD></TR></TABLE></DIV>
<P align=justify>Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions: </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left ><B>[ &nbsp;] </B></TD>
    <TD align=left width="95%">Written communications pursuant to Rule 425
      under the Securities Act (17 CFR 230.425) </TD></TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="95%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left ><B>[&nbsp; ] </B></TD>
    <TD align=left width="95%">Soliciting material pursuant to Rule 14a-12
      under the Exchange Act (17 CFR 240.14a-12) </TD></TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="95%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left ><B>[&nbsp; ] </B></TD>
    <TD align=left width="95%">Pre-commencement communications pursuant to
      Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d- 2(b)) </TD></TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="95%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left ><B>[ &nbsp;] </B></TD>
    <TD align=left width="95%">Pre-commencement communications pursuant to
      Rule 13e-4(c) under Exchange Act (17 CFR 240.13e-4(c))
</TD></TR></TABLE><BR>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_2></A>
<P align=justify><B>Item 1.01 Entry into a Material Definitive Agreement
</B></P>
<P align=justify><B>Item 3.02 Unregistered Sales of Equity Securities </B></P>
<P align=justify>On August 17, 2015, the Company cancelled and returned to
treasury, the 500,000 common shares issued on July 22, 2015, at $0.17 per share
to Docherty Management, wholly owned company by the President of the Company and
issued 420,000 common shares of the Company at $0.20 per share to Docherty
Management and cash compensation for taxes of $16,000 pursuant to the terms of
the consulting agreement signed on March 26, 2015. </P>
<P align=justify>The Company issued the units to one (1) non-US persons in an
off-shore transaction pursuant to the exemption from registration provided for
under Regulation S, promulgated under the United States Securities Act of 1933,
as amended. Each of the subscribers represented that they were not a &#147;US person&#148;
as such term is defined in Regulation S.</P>
<P align=justify>The securities referred to herein will not be and have not been
registered under the United States Securities Act of 1933, as amended, and may
not be offered or sold in the United States absent registration or an applicable
exemption from registration requirements. </P>
<P align=justify><B>Item 7.01 Regulation FD Disclosure. </B></P>
<P align=justify>A copy of the news release announcing the share issuance is
filed as exhibit 99.1 to this current report and is hereby incorporated by
reference. </P>
<P align=justify><B>ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS. </B></P>
<P align=justify>(d) Exhibits.</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD vAlign=top noWrap align=center ><B>Exhibit No.</B> </TD>
    <TD vAlign=top noWrap align=center width="90%"><B>Description</B> </TD></TR>
  <TR vAlign=top>
    <TD vAlign=top align=center bgColor=#eeeeee ><a href="exhibit99-1.htm">99.1</a></TD>
    <TD vAlign=top align=left width="90%" bgColor=#eeeeee><a href="exhibit99-1.htm">Press Release dated August 17, 2015</a></TD>
  </TR></TABLE>
<P align=center><B>SIGNATURES </B></P>
<P align=justify>Pursuant to the requirements of the Securities Exchange Act of
1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P>
<P align=justify>Dated: August 17, 2015 </P>
<DIV>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="50%" border=0>

  <TR vAlign=top>
    <TD align=left >&nbsp; </TD>
    <TD align=left width="80%">Lexaria Corp. </TD></TR>
  <TR vAlign=top>
    <TD align=left >(Signature) </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left
      width="80%">By:&nbsp;&nbsp;&nbsp;&nbsp; &#147;<I>/s/ Chris Bunka&#148;</I> </TD></TR>
  <TR vAlign=top>
    <TD align=left >&nbsp; </TD>
    <TD align=left width="80%">Chris Bunka </TD></TR>
  <TR vAlign=top>
    <TD align=left >&nbsp; </TD>
    <TD align=left width="80%">President &amp; CEO
</TD></TR></TABLE></DIV><BR>
<HR align=center width="100%" color=black noShade SIZE=5>

</BODY>

</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
   <TITLE>Lexaria Corp.: Exhibit 99.1 - Filed by newsfilecorp.com</TITLE>
   <META name="HandheldFriendly" content="true">
</HEAD>

<BODY style="font-size:10pt;">

<HR noshade align="center" width=100% size=3 color="black">
<!--$$/page=--><A name=page_1></A>
<P align=center><B>Lexaria Issues Shares as per Management Contract </B></P>
<P align=justify>Kelowna, BC / August 17, 2015 / Lexaria, Corp. (OTCQB:LXRP)
(CSE:LXX) (the &#147;Company&#148;) announces it has cancelled the 500,000 restricted
common shares issued on July 22, 2015, as per an existing management consulting
contract, to Docherty Management Limited. </P>
<P align=justify>In their place, 420,000 restricted common shares have been
awarded to Docherty Management Limited as well as US$16,000 in order to
compensate for the estimated tax burden of receiving restricted common shares
that are not freely tradable. </P>
<P align=justify>All issued shares will be subject to a hold period, for any
resale into the USA under Rule 144, of six months and one day. There are no
proceeds received by the Company. The Issuance is subject to normal regulatory
approvals.</P>
<P align=justify><B>The securities referred to herein will not be or have not
been registered under the United States Securities Act of 1933, as amended, and
may not be offered or sold in the United States absent registration or an
applicable exemption from registration requirements. </B></P>
<P align=justify>About Lexaria <BR>Lexaria is a food sciences company focused on
the delivery of hemp oil compounds procured from legal, agricultural hemp,
through gourmet foods based upon its proprietary infusion technologies.
www.lexariaenergy.com </P>
<P align=justify>About ViPova<SUP>TM</SUP> <BR>ViPova<SUP>TM</SUP> uses only
legal hemp oil extracts, grown from agricultural hemp in locations where it is
legal to do so, in ViPova<SUP>TM</SUP>-branded tea. ViPova<SUP>TM</SUP> uses its
patent-pending process to infuse concentrated amounts of hemp oil within lipids
in its tea, providing more bioactivity and comfort to the body during the
absorption process. Only ViPova<SUP>TM</SUP> has this ground-breaking technology
for hemp oil/lipid infusion. www.vipova.com </P>
<P align=justify>FOR FURTHER INFORMATION PLEASE CONTACT:</P>
<P align=justify>Lexaria Corp.<BR>Chris Bunka<BR>Chairman &amp; CEO<BR>(250)
765-6424 </P>


<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_2></A>
<P align=justify>FORWARD-LOOKING STATEMENTS </P><P align=justify>This release includes forward-looking statements. Statements
which are not historical facts are forward-looking statements. The Company makes
forward-looking public statements concerning its expected future financial position, results of operations, cash flows,
financing plans, business strategy, products and services, competitive
positions, growth opportunities, plans and objectives of management for future
operations, including statements that include words such as "anticipate," "if,"
"believe," "plan," "estimate," "expect," "intend," "may," "could," "should,"
"will," and other similar expressions are forward-looking statements. Such
forward-looking statements are estimates reflecting the Company's best judgment
based upon current information and involve a number of risks and uncertainties,
and there can be no assurance that other factors will not affect the accuracy of
such forward-looking statements. Access to capital, or lack thereof, is a major
risk and there is no assurance that the Company will be able to raise required
working capital. Factors which could cause actual results to differ materially
from those estimated by the Company include, but are not limited to, government
regulation, managing and maintaining growth, the effect of adverse publicity,
litigation, competition and other factors which may be identified from time to
time in the Company's public announcements and filings. There is no assurance
that the medical marijuana, hemp oil sector, or alternative health businesses
will provide any benefit to Lexaria, or that the Company will experience any
growth through participation in these sectors. There is no assurance that
existing capital is sufficient for the Company's needs or that it will need to
attempt to raise additional capital. There is no assurance that any planned
corporate activity, business venture, or initiative will be pursued, or if
pursued, will be successful. There is no assurance that any hemp oil or
cannabinoid-based product will promote, assist, or maintain any beneficial human
health conditions whatsoever. There is no assurance that the cannabinoid/lipid
infusion technology will provide any increase in bioavailability to any
individual person. No statement herein has been evaluated by the Food and Drug
Administration (FDA). ViPova<SUP>TM</SUP> products are not intended to diagnose,
treat, cure or prevent any disease. </P>
<P align=justify><I>The CSE has not reviewed and does not accept responsibility
for the adequacy or accuracy of this release. </I></P>
<HR align=center width="100%" color=black noShade SIZE=5>

</BODY>

</HTML>

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
